Journal profile · Neurosciences
Purinergic Signalling
ISSN 1573-9538 · eISSN 1573-9546 · Springer Netherlands · NETHERLANDS · Quarterly · Founded 2004
Purinergic Signalling: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.52; hybrid open access; APC about USD 4,690; median 98 days to acceptance (85 articles, last 24 months); community-reported acceptance: fairly easy; 46 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Purinergic Signalling is published by Springer Netherlands and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Adenosine and Purinergic Signaling, Neuroscience of respiration and sleep and Receptor Mechanisms and Signaling, together about 56.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells. There is both short-term purinergic signalling in transmission and secretion and long-term (trophic) signalling in controlling cell proliferation, differentiation, motility and death in development and regeneration and there is increasing interest in the roles of purines and pyrimidines in pathophysiological conditions and their therapeutic potential in disease. At the molecular level, rapid progress has been made in understanding the mechanisms of nucleotide and nucleoside release, their extracellular metabolism, the intracellular signalling cascades elicited by receptor activation and the cross-talk with other essential signalling pathways. The rapidly growing interest in purinergic signalling with its exceptionally wide spectrum of signalling functions in health and disease makes this journal devoted to purinergic signalling attractive to both basic scientists and clinicians. Purinergic Signalling publishes: Original Research Articles, Short Communications, Reviews, Commentaries, ’Hot’ Topics and Controversies, as well as Meeting Reports.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief Charles KennedyPublisher website
Editorial board by country: 1 in mainland China (about 1%); most named United States 17, United Kingdom 8, Italy 6, Germany 5, France 4 (69 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Adenosine and Purinergic SignalingBiochemistry, Genetics and Molecular Biology45%
- Neuroscience of respiration and sleepNeuroscience7.8%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology4%
- Vagus Nerve Stimulation ResearchNeuroscience3.9%
- Neurological Complications and SyndromesMedicine3.4%
- Adolescent and Pediatric HealthcareHealth Professions3.3%
- Neuroscience and Neuropharmacology ResearchNeuroscience2.9%
- Pharmacological Receptor Mechanisms and EffectsBiochemistry, Genetics and Molecular Biology2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.52LetPub ·
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.3Publisher website ·
- CiteScore 2026-06
- 5.2LetPub ·
- SJR 2026-06
- 0.86LetPub ·
- SNIP 2026-06
- 0.88LetPub ·
- h-index
- 52LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 726OpenAlex ·
- 2-year mean citedness
- 2.59OpenAlex ·
- Self-citation rate
- 16%LetPub ·
- Share of gold OA articles
- 37.89%LetPub ·
Volume
- Articles per year
- 35LetPub ·
- Downloads per year (publisher) 2025
- 379,300Publisher website ·
Articles by year OpenAlex count · 1,259 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 77 | 76 | 57 |
| 2025 | 46 | 37 | 81 |
| 2024 | 81 | 79 | 390 |
| 2023 | 70 | 70 | 417 |
| 2022 | 84 | 84 | 1,020 |
| 2021 | 69 | 69 | 1,156 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
98 daysMedian, submission to acceptance · P25–P75 70 days – 145 days
- Acceptance to online
- median 17 days (85 articles)
- Submission to online
- median 133 days
- Sample
- 85 articles with submission and acceptance dates (137 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,690 / EUR 3,690 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted12
- commentaryPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- hot topics and controversiesPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- journal clubJournal Club – These discuss 1-3 high-quality papers that comprise significant advances in the field and published in journals other than Purinergic Signalling.Length not stated
- letters to the editorPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- meeting reportsPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- methodologyMethodology – The Methodology article type denotes an article that presents a new experimental procedure or computational method, test or procedure, an improvem…Length not stated
- original research articlePurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- original research articlesPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- reviewPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- reviewsPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- short communicationPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
- short communicationsPurinergic Signalling accepts original research articles, reviews, short communications, letters to the editor, hot topics and controversies and meeting reports…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
LLMs do not satisfy authorship criteria; LLM use must be documented in the Methods section. Model summary
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
Originality and exclusivity required; publication approved by all co-authors and responsible authorities. Model summary
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
Authors must disclose financial or non-financial competing interests. Model summary
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
Data, materials, software and code must support published claims and comply with field standards. Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Journal is a COPE member and follows COPE guidelines on misconduct. Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Purinergic Signalling, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Authors may suggest or exclude reviewers; suggested reviewers must be independent of the work. Model summary
Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts. When suggesting reviewers, authors should make sure they are totally independent and not connected to the work in any way.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Netherlands
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Quarterly
- Founded
- 2004
- ISSN
- 1573-9538
- Electronic ISSN
- 1573-9546
- Society / sponsor
- International Purine Club
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Purinergic Signalling
What CAS zone is Purinergic Signalling in?
In the 2025 upgraded edition of the CAS Journal Ranking, Purinergic Signalling is in Zone 4 of Medicine, and in Zone 4 of the minor category Neurosciences. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Purinergic Signalling?
The latest impact factor listed by LetPub is 2.52; CiteScore 5.2, h-index 79.
How long does peer review take at Purinergic Signalling?
Based on the dates recorded on 85 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 70–145 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Purinergic Signalling?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Purinergic Signalling based?
Of the 69 board members whose country the journal's board page names, 1 (about 1%) are in mainland China; the countries named most often are United States (17), United Kingdom (8) and Italy (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Purinergic Signalling?
According to LetPub and DOAJ records, Purinergic Signalling is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Purinergic Signalling open access, and what is the APC?
Purinergic Signalling is a hybrid journal. For open-access publication: APC about USD 4,690.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .